SCHEMBL3689617

SCHEMBL3689617

Fc1cccc(C2CCN(C(=S)c3nc4c(C(F)(F)F)cc(-c5ccoc5)cn4c3Cl)C2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD5 Q86SK9 8/20 0.40
CNR1 P21554 1/20 0.32
NPC1 O15118 3/20 0.32
RAB9A P51151 3/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
TYRO3 Q06418 1/20 0.32
MERTK Q12866 1/20 0.32
MLYCD O95822 1/20 0.31
MAPT P10636 2/20 0.30
GAA P10253 1/20 0.30
SCD O00767 2/20 0.30
TLR9 Q9NR96 1/20 0.30
TLR8 Q9NR97 1/20 0.30
TLR7 Q9NYK1 1/20 0.30
MEN1 O00255 1/20 0.30
LMNA P02545 1/20 0.30
HTT P42858 1/20 0.30
RECQL P46063 1/20 0.30
KMT2A Q03164 1/20 0.30
CHRM4 P08173 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3694950 0.92 SCD5 (0.46) SCD5CNR1NPC1RAB9ASCD
SCHEMBL3694774 0.89 SCD5 (0.45) SCD5CNR1
SCHEMBL3698154 0.88 SCD5 (0.42) SCD5RAB9AKMT2A
SCHEMBL3690171 0.85 SCD5 (0.39) SCD5CNR1NPC1KMT2ACHRM4
SCHEMBL3688724 0.85 SCD5 (0.41) SCD5NPC1KMT2A
SCHEMBL3691914 0.84 SCD5 (0.44) SCD5CNR1NPC1RAB9ATYRO3
SCHEMBL3691240 0.83 SCD5 (0.48) SCD5NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL3691242 0.83 SCD5 (0.48) SCD5NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL3692964 0.83 SCD5 (0.48) SCD5NPC1RAB9ASMN1; SMN2MAPT
SCHEMBL3696219 0.83 SCD5 (0.40) SCD5TYRO3MERTKSCDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
EP-2187883-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2010-05-26 EP disclosed
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections GLAXOSMITHKLINE LLC 2009-07-09 US disclosed
WO-2009023179-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections OAT, HAVCR2, CPS1 SCD5 2314/4885CNR1 524/4885NPC1 229/4885
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections OAT, HAVCR2, CPS1 SCD5 2314/4885CNR1 524/4885NPC1 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.